CDKN2A and synovial sarcoma: The detection of a CDKN2A deletion has been recognized in a recent study as a potential biomarker for poor prognosis in soft tissue sarcomas, including subtypes such as SS, malignant peripheral nerve sheath tumor, sarcoma NOS, and undifferentiated pleomorphic sarcoma.24